Following the registration of the corresponding amendment to the Articles of Association in the Commercial Register, former Darwin AG (ISIN DE000A3C35W0) now operates under the name Novogenia AG. The name change, approved at the Annual General Meeting on June 26, 2026, is a strategic move to reinforce the company's focus on its core operating brand and unify its market presence with customers, business partners, investors, and the broader community.
The Group's core operating business and future growth are primarily driven by its wholly owned subsidiary, Novogenia GmbH, which has been active in human genetics for many years. Novogenia GmbH develops and sells personalized products based on genetic analysis, and the Novogenia brand is synonymous with in-depth scientific expertise and ongoing technological innovation. The renaming is part of a strategic process to standardize the company's brand identity, simplify corporate structure and communication, and create a consistent image across all target groups. This move supports clearer positioning toward customers, partners, investors, the public, and the capital market.
“Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities. This enhances the visibility and recognition of our Group while reinforcing our ambition to establish Novogenia as a leading international provider of personalized healthcare and longevity solutions, as well as a strong and recognizable brand in the capital market,” says Dr. Daniel Wallerstorfer, CEO of Novogenia AG.
The name change has no impact on the company's strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged. For more information, visit Novogenia AG.
